Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.
Klee described avexitide as a
What Happened? A number of stocks jumped in the afternoon session after the CPI data showed food away from home rose only 0.3% in May, well within manageable...
What Happened? A number of stocks jumped in the afternoon session after the CPI data showed food away from home rose only 0.3% in May, well within manageable...
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
What Happened? A number of stocks jumped in the afternoon session after markets rotated into defensive names following the release of the May CPI report. The...
What Happened? A number of stocks jumped in the afternoon session as markets rotated into defensive names following the release of the May CPI report. The he...
What Happened? Shares of financial services company Robinhood (NASDAQ:HOOD) jumped 6.4% in the afternoon session after it received regulatory approval for it...
Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for a planned leadership transition.
Speaking at the Goldman Sachs Global Healthcare Conference, Chai
Altimmune (NASDAQ:ALT) management used an appearance at the Goldman Sachs Global Healthcare Conference to outline the company’s focus on pemvidutide, its lead metabolic and liver disease drug candidate, and to discuss the planned Phase 3 program in metabolic dysfunction-associated steatohepatitis, o
The SpaceX IPO has Wall Street debating trillion-dollar valuations. Luke Lango argues the selloff it triggered is actually the buying opportunity investors have been waiting for in Corning, Ciena, Broadcom, and Redwire.
CG Oncology (NASDAQ:CGON) Chief Executive Officer Arthur outlined the company’s upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-musc
What Happened? A number of stocks fell in the afternoon session after Trump said a US-Iran deal could come in "two or three days," pulling energy equities sh...
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches.
Speaking at a Gol
Alnylam Pharmaceuticals (NASDAQ:ALNY) executives outlined the company’s 2030 financial targets, TTR franchise strategy and near-term pipeline priorities during a Goldman Sachs event hosted by analyst Salveen Richter.
Jeff Poulton, Alnylam’s chief financial officer, said the company’s “Alnylam 2030”
What Happened? Shares of alternate site health provider Option Care Health (NASDAQ:OPCH) jumped 3.7% in the morning session after Goldman Sachs initiated cov...
